Neck artery immune-therapy vs IV for head and neck cancer
Part of Cancer clinical trials.
This trial compares giving immune therapy into the neck artery versus giving it through a vein (IV) for people with head and neck cancers. It aims to see which method works better and is safer by helping the immune system attack the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Have head and neck cancer confirmed by tissue biopsy (microscope test)
- Be 18 to 80 years old, and your doctors expect you to live more than 3 months
- Be well enough for study treatment (ECOG score less than 2)
- Have “measurable” tumors on scans that can be tracked over time
- Recent blood tests must meet targets (white blood cells, hemoglobin, platelets, liver function, kidney function, and clotting)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at whether giving an immunotherapy drug (a PD-1 inhibitor) after surgery is better than giving radiation therapy for people with advanced head and neck cancer who had a complete response to chemotherapy and immunotherapy before surgery. The goal is to prevent the cancer from coming back.
This trial compares two different treatments for people who have already had surgery for advanced head and neck cancer and responded very well to chemotherapy plus immunotherapy before surgery. It tests whether continuing with immunotherapy or receiving radiation therapy is better at preventing the cancer from coming back.
This trial tests a combination of chemotherapy directly into an artery, radiation, and immunotherapy for advanced head and neck cancer. It may offer a new treatment option for people whose cancer hasn't spread to other parts of the body.
This trial tests an experimental treatment that is injected directly into the tumor to stimulate your immune system to fight the cancer. It is for people with head and neck cancer who have not been helped by prior treatments or who are scheduled for surgery.
This trial tests a personalized radiotherapy approach after a few rounds of chemo-immunotherapy for people with HPV-negative head and neck cancer. It aims to adjust the radiation dose based on how the tumor responds, possibly reducing side effects while still controlling the cancer.
This trial tests a new immune cell therapy (GT201) combined with a PD-1 inhibitor for advanced head and neck cancer. It aims to see if your own immune cells, collected from your tumor, can be boosted to fight the cancer.
Hear when a new Head/Neck Neoplasm trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.